B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

112.10 +0.71 (+0.64%)
Official Closing Price Updated: 4:10 PM EDT, Aug 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,420,993
Open 111.79
Bid (Size) 111.50 (2)
Ask (Size) 112.18 (2)
Prev. Close 111.39
Today's Range 111.05 - 112.15
52wk Range 89.67 - 121.64
Shares Outstanding 1,750,942,289
Dividend Yield 1.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Abbott Laboratories, Nu Holdings And More On CNBC's 'Final Trades'
Abbott Laboratories has a strong pipeline and the stock is starting to move, according to Karen Firestone of Aureus Asset Management. 
Via Benzinga

Performance

YTD
+2.05%
+2.05%
1 Month
+8.08%
+8.08%
3 Month
+6.95%
+6.95%
6 Month
-4.90%
-4.90%
1 Year
+6.61%
+6.61%

More News

Read More
Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.
Via The Motley Fool
Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?
Via The Motley Fool
3 Stocks Retirees Should Absolutely Love
Via The Motley Fool
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Via FinancialNewsMedia
Chips, Glorious Chips!
Via The Motley Fool
3 Dividend Growth Stocks to Buy Hand Over Fist in August
Via The Motley Fool
Large Cap Biopharma And Healthcare, A Port In A Storm
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Via The Motley Fool
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Via Investor's Business Daily
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Via The Motley Fool
7 Leading MedTech Stocks for Next-Gen Health Solutions
Via InvestorPlace
Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: 'I Would Pick Some Up Tomorrow'
Via Benzinga
Topics Economy
Exposures Interest Rates
Healthcare Stocks Are Coming On Strong In July Led By Biotech
Via Talk Markets
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
Via InvestorPlace
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
Via InvestorPlace
Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.
Via InvestorPlace
3 High-Yield Dividend Stocks That Are Looking Super Hot
Via InvestorPlace
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
US Stocks Look To Extend Gains Ahead Of Key Tech Earnings, FOMC Meeting: Analyst Says This 'Could Serve As A Fundamental Catalyst For Small And Mid-Cap'
Via Benzinga
Abbott Laboratories Tumble Nearly 8% In Pre-Market After US Jury Charges $495M Penalty For Disease Causing Baby Formula
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Is Beaten-Down Dexcom Stock a Buy on the Dip?
Via The Motley Fool
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.